Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Goldman Sachs lowers India's 2026 growth forecast to 5.9%, predicts a 50 basis point rate hike

Goldman Sachs lowers India's 2026 growth forecast to 5.9%, predicts a 50 basis point rate hike

汇通财经汇通财经2026/03/24 06:02
Show original
(1) In a report released on Tuesday, Goldman Sachs lowered its economic growth forecast for India in the 2026 calendar year from the previous 7% to 5.9%. The main reasons are the surge in oil prices caused by the Iran war and supply disruptions in the Strait of Hormuz. As a net energy importer, India faces significant risks in foreign exchange, inflation, and fiscal stability. (2) Based on new assumptions regarding oil prices and the duration of supply disruptions, Goldman Sachs forecasts Brent crude oil prices will reach highs of $105 in March and $115 in April, then fall back to $80 in the fourth quarter. It is expected that the disruption in oil flow through the Strait of Hormuz will last until mid-April and return to normal within 30 days thereafter. (3) Affected by these factors, Goldman Sachs raised its inflation forecast for India in 2026 from the previous 3.9% to 4.6%, and predicts the policy interest rate will be increased by 50 basis points.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.

Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.

智通财经•2026/10/09 07:09

Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.

智通财经•2026/10/09 07:08

Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000

PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.

智通财经•2026/10/09 06:47